Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: VLAD who wrote (18620)	2/9/1999 7:18:00 PM
From: VLAD	Respond to of 23519

More voodoo, biospace.com CNBC report on Fen/Phen now on. Over 1,700 lawsuits filed so far and only about 24 scientifically confirmed cases of valve damage. Viagra's day will come. Be patient!

To: VLAD who wrote (18620)	2/9/1999 8:00:00 PM
From: DaiS	Read Replies (1) \| Respond to of 23519

Vlad, I confess that I had not thought of monkeys before! Is this usual for drug trials.....cetainly not for carcinogenicity testing I thought, usually a smaller mammal is sufficient, cheaper and kinder to monkeys? I do not see special problems here, given that there are already 100s of gene therapy trials already in progress worldwide (and there are now two in phaseIII). As I said before, there is theoretical justification and empricial evidence for efficacy and safety. If it works in rats it'll work in monkeys, remember the hslo gene used is human. I believe that the penis of chimps is quite large like our own and there could be safety considerations that suggest a chimp experiment...really I would be surprised. What I would like to know is what happens when these rejuvenated old rats are introduced to lady rats rather than having electrodes stuck in 'em....what is the mount rate compared with old impotent rats? I will find out what I can. DaiS